Follicular fluid is the liquid bath inside each ovarian follicle, and it is far more than a passive ultrafiltrate of blood plasma. It is a dynamic biological compartment formed through selective transfer of circulating constituents across the blood-follicle barrier together with secretory products generated locally by the oocyte, cumulus cells, granulosa cells and theca cells. Its composition integrates systemic endocrine inputs with bidirectional oocyte-somatic cell communication, steroidogenesis, metabolic coupling, extracellular-matrix remodeling, periovulatory inflammation, redox homeostasis, mitochondrial function and angiogenesis. In effect, follicular fluid is a molecular record of the follicle’s physiological state, and because it is aspirated during every IVF cycle, it offers a minimally invasive window into the microenvironment that shaped each egg.

The review, led by researchers at China Medical University Hospital in Taiwan, synthesizes mechanistic and clinical evidence on follicular-fluid biomarkers associated with oocyte maturity, fertilization, embryo development, blastocyst formation, implantation and live birth. Particular attention goes to granulosa cell-associated signaling networks involving epidermal growth factor-like ligands, pentraxin 3, transforming growth factor-beta and bone morphogenetic protein family members, activins and follistatin, cytokines, steroid hormones, metabolic intermediates, lipids, oxidative-damage markers and extracellular-matrix components. Among these candidates, the steroid hormones progesterone and anti-Müllerian hormone measured in individual follicles have the most direct observational evidence, with associations reported for fertilization, embryo morphology, blastocyst development and even live birth after fresh single-embryo transfer.

Yet the review’s central conclusion is sobering: no single molecule in follicular fluid has demonstrated sufficient reproducibility, discrimination and calibration to support routine clinical prediction. The reasons are deeply rooted in follicular biology. Growth factors are pleiotropic and context-dependent, so the biological significance of one concentration cannot be interpreted independently of related ligands, receptors, binding proteins and downstream signaling activity. Functional redundancy within the transforming growth factor-beta superfamily means that alterations in one molecule may be compensated for by changes elsewhere in the network, so an apparently normal value does not necessarily indicate normal pathway activity. Follicular signaling is also temporally and spatially organized, meaning that concentrations measured at retrieval represent a time-specific composite influenced by follicle size, maturation status, ovarian stimulation, trigger regimen and the interval between triggering and aspiration.

Methodological heterogeneity compounds the problem. Patient phenotype, ovarian-stimulation regimen, follicular stage, sampling strategy, preanalytical handling, analytical platform and outcome definition all influence measured concentrations. Follicular heterogeneity and the statistical non-independence of multiple oocytes obtained from the same patient further complicate biomarker evaluation, because several follicles from one woman are biologically correlated rather than independent observations. Within-patient variability in follicular-fluid estradiol has been reported to be approximately twice the between-patient variability, underscoring how pooling fluid from multiple follicles obscures follicle-specific signals and prevents reliable linkage between a biochemical measurement and its corresponding oocyte or embryo.

The authors therefore propose a decisive transition from single-analyte measurements toward mechanism-informed, outcome-specific multianalyte panels that integrate follicular-fluid measurements with cumulus-cell or granulosa-cell transcriptomic, proteomic, metabolomic and lipidomic features. Phenotype-specific models, particularly for polycystic ovary syndrome, may further improve biological interpretation. Advanced mass-spectrometry approaches such as SWATH, a data-independent acquisition method that sequentially isolates and fragments precursor ions across predefined mass-to-charge windows, can improve analytical coverage and reproducibility for low-abundance endogenous metabolites that traditional techniques miss. A preliminary SWATH-based study identified elevated free fatty acids, 3-hydroxynonanoyl carnitine, eicosapentaenoic acid, deoxycorticosterone, phenylalanine and leucine, together with reduced lysophosphatidylcholines and phytosphingosine, in follicular fluid from women with polycystic ovary syndrome, suggesting disturbances in fatty-acid oxidation, phospholipid turnover, amino-acid metabolism and steroidogenesis.

Several biologically coherent modules emerge as promising panel foundations. Periovulatory epidermal growth factor signaling, captured by amphiregulin, reflects luteinizing hormone-induced activation of cumulus expansion and prostaglandin synthesis. Pentraxin 3, an essential structural component of the cumulus extracellular matrix, integrates stimulatory EGF-like signaling with inhibitory inputs from BMP4, BMP7, BMP6, activin A, GDF8 and TGF-beta1, making it a downstream convergence point rather than a readout of a single pathway. The activin-follistatin balance, the progesterone-to-estradiol ratio, redox markers such as glutathione and 8-hydroxy-2′-deoxyguanosine, cell-free mitochondrial DNA, acylcarnitines and lysophosphatidylcholines each represent complementary biological domains. An integrated blastocyst panel could combine metabolic function, mitochondrial or oxidative injury, and follicular-cell support in a single signature.

Clinical translation, however, demands far more than biological plausibility. The review specifies that progress will require standardized individual-follicle sampling, one-to-one linkage between biomarkers and oocyte or embryo outcomes, targeted assay development with documented accuracy, precision, linearity, recovery, stability and matrix effects, multilevel statistical modeling that accounts for follicles nested within women, independent prospective validation across different populations and laboratory platforms, and demonstration of incremental clinical utility beyond established patient and embryological variables. Mechanistic plausibility, clinical association and predictive utility must be regarded as distinct levels of evidence, because experimental changes in gene or protein expression in cultured granulosa-lutein cells do not necessarily produce corresponding changes in follicular-fluid concentrations.

The ultimate goal is a parsimonious and reproducible biomarker panel that complements, rather than replaces, conventional embryological assessment and supports more individualized IVF decision-making. Because follicular fluid is obtained only after follicular aspiration, its most plausible near-term role is research, prognostic assessment or prioritization of sibling oocytes and embryos rather than modification of the ongoing stimulation cycle. Until analytical validity, external reproducibility, clinical utility, feasibility and cost-effectiveness are demonstrated, the proposed combinations should remain investigational. Still, the vision is compelling: a small, interpretable, clinically scalable molecular readout of each follicle’s inner life, finally giving embryologists a way to see not just what an egg looks like, but what it is made of.

Subject of Research: Follicular fluid biomarkers for IVF outcome prediction

Article Title: Integrative follicular fluid biomarkers for oocyte competence and IVF outcomes: from molecular networks to multianalyte panels

Article References: Chen, C.-Y., Lu, Y.-T., Chang, P.-H., Chen, H.-J., Hsueh, Y.-W., Chang, C.-W., Hsu, H.-C., Yang, T.-C., Chang, Y.-Y., & Chang, H.-M. (2026). Integrative follicular fluid biomarkers for oocyte competence and IVF outcomes: from molecular networks to multianalyte panels. Frontiers in Endocrinology, 17, Article 1962631. https://doi.org/10.3389/fendo.2026.1962631

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1962631

Keywords: IVF, follicular fluid, biomarkers, oocyte competence, reproductive medicine, embryology, omics, Integrative, follicular, fluid, oocyte, competence

The research team, working at the International Center for Reproductive Medicine, analyzed 39 couples in which one partner carried an autosomal reciprocal translocation and who underwent in vitro fertilization with preimplantation genetic testing for structural rearrangements between 2016 and 2021. The dataset comprised 306 cleavage-stage embryos, examined on day three, and trophectoderm cells from 93 blastocyst-stage embryos, examined on day five or six. Genetic testing relied on fluorescent in situ hybridization, next-generation sequencing, or array comparative genomic hybridization, allowing the researchers to infer which segregation mode had produced each embryo. Karyotypes were confirmed on peripheral blood lymphocytes, and all participants signed informed consent.

Across all 399 embryos, alternate segregation, the only mode that yields genetically normal or balanced gametes, was the most common pattern, detected in 32 percent of cases. Adjacent-1 segregation followed at 24 percent, the 3:1 mode at 21 percent, adjacent-2 at 13 percent, and the rare 4:0 pattern in just 1 percent. In 9 percent of embryos the segregation mode could not be determined because of mosaicism or polyploidy, and these were excluded from further analysis. The overall picture confirms that even though alternate segregation dominates, carriers still produce a strikingly high proportion of unbalanced gametes, which underlies their elevated risk of reproductive failure.

The most dramatic finding emerged when the researchers compared day-three and day-five/six embryos. The frequency of 3:1 segregation collapsed from 28 percent at the cleavage stage to just 4 percent at the blastocyst stage, a difference that was highly statistically significant with a p-value below 0.0001. Alternate segregation rose from 34 to 45 percent and adjacent-1 from 24 to 33 percent, though these increases did not reach statistical significance, likely because of the modest sample size. The explanation, the authors argue, is natural selection: embryos produced by 3:1 segregation carry tertiary or interchange trisomies and monosomies, which represent far larger chromosomal imbalances than the partial trisomies and monosomies of adjacent-1 products, and such heavily unbalanced embryos rarely survive to the blastocyst stage.

To understand what drives pathological segregation in the first place, the team turned to cleavage-stage embryos, where the embryonic genome has not yet triggered substantial selection, and classified each translocation by three quadrivalent features. The degree of asymmetry was quantified by measuring translocated and centric segment lengths with the UCSC genome browser on the GRCh38/hg38 assembly, and calculating the ratio of the longest to the shortest segment of each type; ratios of two or more in both categories defined severe asymmetry. Terminal breakpoints were defined as breakpoints falling within the distal 20 percent of a chromosome arm. Acrocentric involvement was recorded whenever chromosome 13, 14, 15, 21, or 22 participated in the rearrangement.

Of the 39 translocations, 28 showed mild asymmetry and 11 severe asymmetry, but asymmetry degree had no detectable effect on the frequency of any segregation mode at the cleavage stage. Acrocentric involvement, present in 18 cases, shifted the balance between pathological modes: it increased the frequency of adjacent-2 segregation and reduced adjacent-1, without altering the production of balanced embryos. The decisive factor, however, was the presence of terminal breakpoints, found in seven translocations. Embryos from carriers with terminal breakpoints showed a significantly higher frequency of 3:1 segregation, with a p-value of 0.002, while the rate of balanced embryo formation remained unchanged.

The viability analysis revealed an unexpected twist. When embryos from carriers with terminal breakpoints were followed to the blastocyst stage, significantly more embryos derived from alternate segregation and, strikingly, from adjacent-1 segregation survived, with p-values of 0.0513 and 0.0007 respectively. The authors attribute this to the small size of the translocated segments in rearrangements with terminal breakpoints. Adjacent-1 products carry partial monosomy or trisomy of the translocated segments only, and when those segments are tiny, the resulting imbalance may fall within the limits compatible with implantation and development. Classical models by Daniel and later Cohen estimated that viable imbalances rarely exceed a few percent of the haploid autosome length, and most adjacent-1 embryos in this cohort fit within those bounds.

This survival effect carries a clinical warning. An embryo that reaches the blastocyst stage after adjacent-1 segregation may look developmentally competent, yet it can harbor an imbalance capable of producing a child with multiple congenital malformations. The findings therefore support preimplantation genetic testing of blastocyst-stage embryos as preferable to cleavage-stage testing for translocation carriers, since blastocyst testing both benefits from natural selection against severely unbalanced embryos and provides a broader genomic assessment. At the same time, the study shows that quadrivalent asymmetry and acrocentric involvement, which earlier work had implicated in segregation patterns, do not appear to influence embryo survival by the blastocyst stage regardless of the preceding segregation mode.

The authors acknowledge limitations, including the small sample size and the fact that only a limited number of chromosomes were analyzed in cleavage-stage embryos, meaning some selection by the blastocyst stage could reflect aneuploidy of chromosomes outside the rearrangement. Even so, the work delivers a coherent picture: terminal breakpoints predispose to 3:1 segregation during gametogenesis, natural selection removes most 3:1 products by day five or six, and the same terminal breakpoints paradoxically enhance the survival of adjacent-1 embryos whose small imbalances may still cause congenital disease. For the estimated one in five hundred people who carry a reciprocal translocation, these patterns promise sharper risk assessment and better-informed counseling in IVF programs.

Subject of Research: Chromosome segregation patterns in human preimplantation embryos from reciprocal translocation carriers

Article Title: Assessment of quadrivalent characteristics influencing chromosome segregation by analyzing human preimplantation embryos from reciprocal translocation carriers

Article References: Tonyan, Z. N., Puppo, I. L., Saifitdinova, A. F., Vavilova, T. V., & Glotov, A. S. (2024). Assessment of quadrivalent characteristics influencing chromosome segregation by analyzing human preimplantation embryos from reciprocal translocation carriers. Comparative Cytogenetics, 18, 1-13. https://doi.org/10.3897/compcytogen.18.115070

Image Credits: AI Generated

DOI: 10.3897/compcytogen.18.115070

Keywords: reciprocal translocation, quadrivalent, chromosome segregation, preimplantation genetic testing, blastocyst, meiosis, terminal breakpoints, acrocentric chromosomes, IVF, PGT-SR, Assessment, characteristics

The original study, published on 01 April 2021, investigated a question that many fertility researchers find compelling: whether routine blood markers measured during ovarian stimulation could serve as early predictors of success in assisted reproduction. Specifically, the authors looked at serum progesterone levels on the day of hCG administration and the ratio of that progesterone level to the number of metaphase II oocytes retrieved. The idea was that these values might help clinicians anticipate IVF/ICSI outcomes before embryo transfer, potentially guiding decisions about cycle management in patients with normal ovarian reserve.

The retraction notice notes that the authors did not explicitly state whether they agreed to the retraction. The notice does not elaborate on the nature of the concerns beyond the similarity between the ROC curves for the progesterone-to-estradiol ratio and for serum progesterone in the two figures. The editors’ decision reflects a standard but serious response in research publishing: when raw data cannot be produced to address questions about figure integrity, confidence in the published results cannot be maintained.

ROC curves, or receiver operating characteristic curves, are a widely used analytical tool in clinical prediction studies. They plot the true positive rate against the false positive rate at various threshold settings, allowing researchers to evaluate how well a biomarker discriminates between patients who will and will not experience a particular outcome. In fertility research, ROC curves are often used to identify cutoff values for hormones like progesterone that might predict clinical pregnancy, live birth, or oocyte quality. When two ROC curves in the same study appear suspiciously similar, particularly when they are supposed to represent different biomarkers, it raises questions about whether the underlying data were processed independently.

The progesterone-to-oocyte ratio concept that the original study explored is part of a broader effort in reproductive medicine to find accessible, low-cost predictors of IVF/ICSI success. Serum progesterone is routinely measured during ovarian stimulation protocols, and elevated progesterone on the day of hCG administration has been associated in some studies with reduced endometrial receptivity and poorer outcomes. The ratio of progesterone to the number of metaphase II oocytes was proposed as a way to account for both the hormonal environment and the ovarian response simultaneously, potentially offering a more nuanced predictor than either value alone.

The retraction notice does not detail the specific statistical concerns or the extent of the similarity between the figures. However, the editors’ decision to retract without author agreement underscores the seriousness with which journals treat questions about data integrity when authors are unable or unwilling to provide raw data for verification. In such cases, the burden of proof rests with the authors to demonstrate that the published results are sound.

This retraction is part of a growing pattern in scientific publishing where journals are increasingly vigilant about figure integrity, data availability, and author responsiveness. The Committee on Publication Ethics, which provides guidance to journals on handling misconduct concerns, recommends that editors seek explanations from authors and request raw data when concerns arise. When authors do not respond or cannot provide adequate documentation, retraction is often the appropriate outcome to protect the scientific record.

For clinicians and researchers who may have cited the original study, the retraction means that the findings should no longer be relied upon as evidence for the predictive value of serum progesterone levels or progesterone-to-oocyte ratios in IVF/ICSI outcomes. The retraction notice is now linked to the original article, ensuring that readers who encounter the study will be aware of its retracted status. The original article remains online but is marked as retracted, following standard practice in open access publishing.

The case highlights the ongoing challenges in maintaining research integrity in fertility and reproductive medicine, where the pressure to publish novel findings about biomarkers and predictors of assisted reproduction success remains high. As analytical tools become more sophisticated and journals adopt more rigorous checks on figure authenticity and data provenance, questions about the reliability of published results are increasingly being raised before they can influence clinical practice. The editors’ decision in this case reflects the importance of raw data availability as a cornerstone of scientific verification.

Subject of Research: Retraction Note: The value of serum progesterone level on day of human chorionic gonadotrophin administration/metaphase II oocyte ratio in predicting IVF/ICSI outcome in patients with normal ovarian reserve

Article Title: Retraction Note: The value of serum progesterone level on day of human chorionic gonadotrophin administration/metaphase II oocyte ratio in predicting IVF/ICSI outcome in patients with normal ovarian reserve

Article References: Mahran, A., Khairy, M., Elkhateeb, R., Hegazy, A. R., Abdelmeged, A., El-Saber Batiha, G., Alsharif, K. F., Hetta, H. F., & Bahaa, H. A. (2026). Retraction Note: The value of serum progesterone level on day of human chorionic gonadotrophin administration/metaphase II oocyte ratio in predicting IVF/ICSI outcome in patients with normal ovarian reserve. Journal of Ovarian Research, 19(1), Article 316. https://doi.org/10.1186/s13048-026-02302-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02302-8

Keywords: Retraction, Journal of Ovarian Research, IVF, ICSI, Progesterone, ROC curves, Research integrity, Fertility research, Note, value, serum, level

Infertility remains a global problem. In the United States, roughly 12 percent of women struggle to conceive or to carry a pregnancy to term, and even after in vitro fertilization and embryo transfer, implantation failure and pregnancy loss are common. When an embryo settles in the wrong place, the consequences can be dire: ectopic pregnancies threaten the life of the mother, while misplaced embryos within the uterus can cause placenta previa and obstruct the birth canal. Despite these clinical stakes, the mechanics of how smooth muscle contractions position embryos have remained poorly understood, because smooth muscle contractile units lack the well-characterized sarcomere architecture of skeletal and cardiac muscle.

The research team, led by Michael Gotthardt at the Max Delbrück Center, revisited titin expression in the uterus using modern tools. Because striated muscle titin isoforms can reach four megadaltons, they require specialized low-resolution agarose gel electrophoresis for separation, whereas the roughly one-megadalton smitin isoform can be resolved by conventional polyacrylamide gels. By overloading agarose gels with uterus lysate and then confirming the identity of the giant band with targeted mass spectrometry, the researchers detected peptides spanning the complete titin amino acid sequence, all the way through to the M-band exons at the protein’s C-terminus. This established, unambiguously, that a full-length titin isoform exists in the uterus, albeit at levels far below those in skeletal muscle and roughly an order of magnitude lower than smitin itself.

To visualize where the protein resides, the team used fluorescence lifetime imaging on uterine smooth muscle cells isolated from mice engineered to carry a fluorescent tag at titin’s C-terminus. The tagged protein displayed a perinuclear and filament-associated pattern that alternated with smooth muscle actin staining, consistent with titin’s integration into the cytoskeletal network that links dense bodies and contractile filaments in smooth muscle cells.

With expression confirmed, the investigators turned to genetics. They crossed mice carrying loxP-flanked M-band exons 1 and 2 of the titin gene with a transgenic line expressing Cre recombinase under the smooth muscle myosin heavy chain promoter, thereby excising the kinase-encoding region specifically in smooth muscle. The knockout animals appeared entirely normal under baseline conditions, with normal body weight, heart weight, estrous cycles, and uterine histology. Ovulation, fertilization, and blastocyst development also proceeded normally. Yet when the researchers looked at implantation, using Evans Blue dye that stains sites of increased stromal vascular permeability, a striking phenotype emerged: in only about 40 percent of knockout females were blastocysts properly localized at embryonic days 4.5 and 5.5. The remaining animals showed reduced numbers of implantation sites, crowding of embryos, or abnormal distribution. Crucially, the number of blastocysts available for implantation was identical between knockout and control animals, meaning the defect lay in the uterus, not the embryo.

The consequences rippled through pregnancy. Uterus-to-bodyweight ratios failed to rise normally after day 5.5, placental weights at term were increased, suggesting compensatory placental adaptation to the suboptimal spacing of embryos, and average litter size at birth fell to less than half that of controls. Heterozygous animals and Cre-positive controls implanted normally, excluding unintended effects of the transgene or germline recombination.

Transcriptomic profiling at day 3.5 revealed that the most deregulated genes clustered in oxytocin signaling and myometrial contraction and relaxation pathways, including Camk2a, Itpr2, Rock1, and Rgs1. This pointed the team toward functional testing. In ex vivo ring myography, uterine rings from knockout animals responded to increasing concentrations of oxytocin with markedly greater peak force, more than 1.8-fold higher maximal contraction rates, and significantly increased area under the force curve starting at just 0.1 nanomolar oxytocin. Remarkably, resting wall tension was unchanged between genotypes, indicating that passive, elastic properties were preserved. This makes biological sense: with full-length titin present at more than two orders of magnitude lower levels than in striated muscle, its contribution to myometrial stiffness is small.

When the researchers tracked uterine wall motion in tissue strips labeled with the fluorescent dye DiI, they uncovered an apparent paradox. Knockout uteri generated more force than controls but displayed fewer movement peaks and more spatially confined displacements after oxytocin stimulation, in both longitudinal and circular fiber directions. The knockout uterus, in other words, does not lack contractile capacity; it lacks coordination. Western blots and laser-capture microdissection proteomics resolved this further: core contractile proteins such as ACTA2, MYH11, and myosin light chain were unchanged within the isolated myometrium, meaning the hypercontractility arose from signaling and coupling reprogramming rather than from extra myofilament content. Instead, the myometrium showed a hyperexcitable profile, with reduced calcium-handling pumps ATP1A2 and SERCA3, loss of the hyperpolarizing SK3 channel, elevated S100G, and increased prostaglandin transporter SLCO2A1, alongside reinforced matrix-remodeling signals including MMP3, DDR2, and integrin beta 3.

The proteomic data also exposed a collapse in a selective autophagy module anchored at titin’s kinase region. Loss of the M-band exons reduced NBR1 while increasing p62/SQSTM1, with MuRF1 unchanged, and triggered compensatory activation of redox pathways marked by TXNIP elevation and KEAP1 reduction, together with an increase in the ubiquitin ligase adaptor FBXO32. The authors interpret the titin M-band in the uterus as a mechanotransductive hub that restrains excitability and synchronizes peristalsis, ensuring embryos are spaced evenly along the uterine horns rather than acting as the main structural determinant of stiffness. They caution that a direct physical interaction between uterine titin and the NBR1/p62 module, and autophagy flux measurements, remain to be demonstrated in future experiments.

The translational implications are tantalizing. In humans, excessive or poorly coordinated uterine contractions around the time of embryo transfer are associated with reduced IVF success, and the authors propose that variants in the TTN gene or its interactors could contribute to unexplained infertility. Biomarkers based on autophagy adaptor levels or extracellular matrix signatures might eventually identify women at risk of implantation failure, and pharmacological strategies to restore calcium buffering, redox balance, or relaxation signaling could optimize peri-implantation uterine motility. Important caveats remain: mice have a bicornuate uterus with two horns, whereas humans have a single cavity with different implantation dynamics, and no direct human evidence yet links TTN variants to implantation failure. Still, by connecting a defined structural element of smooth muscle to the choreography of embryo positioning, the study opens an entirely new molecular window onto one of the most critical and least understood steps of early pregnancy.

Subject of Research: The role of the smooth muscle titin filament system in uterine contractility and embryo implantation

Article Title: The smooth muscle titin filament system regulates uterus contractility and implantation

Article References: Sur, V. J., Fink, C., Bergmann, N., Jüttner, R., Klingeberg, M., Coscia, F., Suarez-Artiles, L., Mertins, P., Fritsch, J. E., Birol, M., Gollasch, M., & Gotthardt, M. (2026). The smooth muscle titin filament system regulates uterus contractility and implantation. iScience, 29(11), Article 117888. https://doi.org/10.1016/j.isci.2026.117888

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117888

Keywords: titin, smooth muscle, uterus, embryo implantation, myometrium, infertility, IVF, oxytocin, mechanotransduction, autophagy, calcium handling, peristalsis

Follitropin delta is a recombinant follicle-stimulating hormone, or FSH, produced in a human cell line, which gives it higher biopotency than earlier recombinant products derived from hamster cells. Because of this increased potency, the drug is measured in micrograms rather than the international units used for other gonadotrophins. When regulators approved it, they endorsed an individualised dosing algorithm that takes a patient’s anti-Müllerian hormone level and body weight into account. That algorithm, however, was validated in gonadotrophin-releasing hormone antagonist protocols culminating in fresh embryo transfer. In freeze-all cycles, where ovarian stimulation is deliberately decoupled from embryo transfer to reduce the risk of ovarian hyperstimulation syndrome and to allow endometrial preparation on the patient’s own timetable, the algorithm’s assumptions no longer hold neatly, and many clinics have found it cumbersome to apply.

The progestin protocol has emerged as an increasingly adopted alternative for freeze-all IVF cycles. Instead of using a GnRH agonist or antagonist to prevent the premature surge of luteinising hormone that could trigger ovulation before egg retrieval, clinicians administer a progestin, a synthetic progesterone-like compound, which suppresses the surge effectively and inexpensively. Combined with the freeze-all strategy, in which all embryos are cryopreserved and transferred in a later, physiologically calmer cycle, the progestin protocol has expanded access to IVF in many settings. Yet no evidence existed on how follitropin delta’s simplified dosing regimens, which had shown promise in antagonist protocols, would perform in this context. The new study set out to fill that gap.

Researchers led by Tien Khac Le of IVFMD Phu Nhuan, My Duc Phu Nhuan Hospital, and colleagues across several Vietnamese institutions conducted a multicentre retrospective cohort study spanning May 2023 to September 2024 at three tertiary hospitals: My Duc Hospital and My Duc Phu Nhuan Hospital in Ho Chi Minh City, and the Family Hospital in Da Nang. They included women undergoing their first IVF or intracytoplasmic sperm injection cycle with a progestin protocol and a freeze-all indication. Patients received either follitropin delta at one of three fixed starting doses of 9, 12, or 18 micrograms per day, or follitropin alfa at 150, 225, or 300 international units per day, with the dose in both groups selected according to the woman’s anti-Müllerian hormone level. This stratified, fixed-dose approach deliberately bypasses the complex individualised algorithm, trading mathematical precision for bedside simplicity.

Because the study was observational rather than randomised, the investigators faced the familiar challenge of confounding: women prescribed one drug might differ systematically from those prescribed the other in age, weight, or ovarian reserve. To address this, they used propensity score matching, a statistical technique that pairs patients from the two treatment groups who share similar baseline characteristics. Matching was performed on age, body mass index, anti-Müllerian hormone, and antral follicle count, the ultrasound-based measure of resting follicles. After matching, 342 women per group were analysed for stimulation and laboratory outcomes, and 315 women in the follitropin alfa group and 314 in the follitropin delta group completed the analysis of their first frozen embryo transfer. The primary outcome was live birth following that first frozen transfer.

The headline result was reassuring equivalence. The live birth rate after the first frozen embryo transfer was 40.1 percent in the follitropin delta group compared with 41.6 percent in the follitropin alfa group, a difference captured by a relative risk of 0.97 with a 95 percent confidence interval of 0.8 to 1.2 and a p value of 0.8. In plain terms, the two regimens produced essentially indistinguishable chances of a baby from the first transfer, and the statistical interval comfortably spans the possibility of no difference at all. For a drug whose potency and dosing logic differ fundamentally from the long-standing standard, that finding carries considerable clinical weight.

Where the regimens diverged was in efficiency. Women receiving follitropin delta completed ovarian stimulation in a median of eight days, compared with nine days in the follitropin alfa group, a difference that was highly statistically significant. Crucially, the shorter stimulation did not come at the cost of follicular yield: the number of follicles measuring at least 14 millimetres and the number of oocytes retrieved were similar between the groups. The authors report that other embryological outcomes, pregnancy outcomes, and neonatal outcomes were also comparable, suggesting that the more potent hormone compressed the stimulation timeline without degrading the quality of the eggs, embryos, or eventual pregnancies that resulted.

Safety findings were equally notable. Not a single case of ovarian hyperstimulation syndrome occurred in either arm of the matched cohort, an outcome that reflects both the freeze-all strategy itself, which removes the pregnancy-driven amplification of the syndrome, and careful dose stratification by ovarian reserve. Ovarian hyperstimulation syndrome remains one of the most feared complications of IVF, and any regimen that maintains live birth rates while keeping that risk at zero in a large cohort will attract attention from clinicians seeking safer stimulation protocols, particularly in settings where high-responder populations are common.

The study’s design does impose limits on how far the conclusions can travel. As a retrospective propensity-matched cohort, it cannot eliminate residual confounding the way a randomised trial would, and the fixed-dose stratification was applied according to local clinical practice rather than a pre-specified protocol. The authors themselves are explicit on this point: while the findings suggest that the pragmatic follitropin delta regimen may offer clinical efficiency in progestin-protocol freeze-all cycles, well-designed prospective randomised controlled trials are required before it can be routinely recommended in clinical practice. The research received no external funding, and the authors declare no competing interests, with ethics approval granted by the Institutional Review Board of My Duc Hospital and patient consent waived given the anonymised, retrospective nature of the data.

Even with those caveats, the study marks a meaningful step in the evolution of personalised ovarian stimulation. Follitropin delta’s individualised algorithm, elegant on paper, has proven difficult to deploy in the protocols that now dominate modern IVF practice, especially freeze-all cycles built on progestin suppression. Demonstrating that a simple three-tier dosing scheme keyed to anti-Müllerian hormone can match the standard drug on live birth while shaving a day off stimulation offers clinics a practical, evidence-grounded option. If randomised trials confirm these results, the microgram-dosed hormone could move from a niche product constrained by its own dosing software to a mainstream tool for ovarian stimulation across the full spectrum of contemporary IVF protocols.

Subject of Research: Follitropin delta dosing for ovarian stimulation in IVF freeze-all cycles using a progestin protocol

Article Title: Novel follitropin delta dosing regimen during in vitro fertilisation using a progestin protocol and freeze-all strategy: a propensity score matching cohort study

Article References: Le, T. K., Nguyen, D. L., Pham, T. D., Le, H. L., Ho, V. N. A., Le, X. T. H., Vo, C. V., Nguyen, T. T. L., Ha, A. N., Ly, T. T., Huynh, B. G., Ho, T. M., & Vuong, L. N. (2026). Novel follitropin delta dosing regimen during in vitro fertilisation using a progestin protocol and freeze-all strategy: a propensity score matching cohort study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02292-7

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02292-7

Keywords: follitropin delta, follitropin alfa, IVF, progestin protocol, freeze-all strategy, frozen embryo transfer, ovarian stimulation, anti-Müllerian hormone, live birth rate, ovarian hyperstimulation syndrome, propensity score matching, reproductive medicine

Ovarian stimulation is the engine of modern in vitro fertilization. For decades, the standard approach has been to start injectable gonadotrophins early in the menstrual cycle, typically on day two or three, and to co-administer a GnRH antagonist partway through the stimulation to prevent a premature surge of luteinizing hormone (LH). Such a surge would otherwise trigger ovulation before the eggs could be retrieved, ruining the cycle. The antagonist acts as a chemical clamp on the pituitary gland, blocking the receptors through which GnRH from the hypothalamus would normally instruct the release of LH and follicle-stimulating hormone. It is an effective safeguard, but it adds injections, cost, and monitoring complexity to an already demanding process.

Late follicular phase stimulation emerged as an alternative concept in the context of freeze-all strategies, in which no fresh embryo transfer takes place. Instead, all embryos are cryopreserved and transferred in a later, unstimulated or artificially prepared cycle. Because the transfer is decoupled from the stimulation, clinicians have more flexibility in how the stimulation itself is conducted. In a late stimulation protocol, gonadotrophins are not started at the beginning of the cycle but later, after a dominant follicle has already been selected by the body’s own hormonal signals. The idea is to recruit the cohort of antral follicles that is naturally available in that cycle while working with, rather than against, the endocrine rhythm of the ovary.

Until now, however, even late stimulation protocols have relied on exogenous pituitary modulators, usually a GnRH antagonist added once stimulation begins, to guard against a premature LH surge. Whether the antagonist could be dropped altogether in late stimulation was an open question, and robust randomized evidence was lacking. The new trial, led by Xiuxian Zhu, Jingwen Lang, and colleagues at Shanghai First Maternity and Infant Hospital affiliated with Tongji University School of Medicine, was designed to answer precisely that question using a non-inferiority framework, the appropriate statistical design when the goal is to show that a simpler treatment is not meaningfully worse than the standard one.

The researchers enrolled 300 infertile women with normal ovulatory function and randomized them one-to-one between February 2022 and October 2023. Half received the conventional GnRH antagonist protocol, with stimulation initiated in the early follicular phase and antagonist co-administration. The other half received the antagonist-free late stimulation protocol, in which gonadotrophin injections began later in the follicular phase without any pituitary-blocking drug. All participants were undergoing IVF or intracytoplasmic sperm injection (ICSI) with a freeze-all strategy, meaning every viable embryo was frozen for later transfer. The trial was registered with the Chinese Clinical Trial Registry (ChiCTR2200055972) and approved by the hospital’s ethics committee, with all participants providing written informed consent.

The primary outcome was the number of usable embryos, a measure that captures the clinically meaningful yield of a stimulation cycle better than raw egg counts alone. In the late stimulation group, the median number of usable embryos was 3 (interquartile range 1 to 5), while in the antagonist group it was also 3 (interquartile range 1 to 4). The median difference between groups was 0, with a 95 percent confidence interval of minus 1 to 0. The prespecified non-inferiority margin was set at the lower bound of that interval, and because the lower bound of minus 1 met the margin, the investigators concluded that the antagonist-free late protocol was non-inferior to the antagonist regimen. In practical terms, women who skipped the antagonist did not end up with fewer embryos fit for freezing and later transfer.

Several secondary outcomes added nuance to this headline result. The total number of oocytes retrieved did not differ significantly between the two groups, but the late stimulation group produced significantly more mature oocytes, with a median of 7 (interquartile range 4 to 10.25) compared with 5.5 (interquartile range 3 to 8) in the antagonist group, a difference that reached statistical significance at P equals 0.018. Maturity matters because only mature oocytes, those that have completed the first meiotic division, can be fertilized. A protocol that yields a higher proportion of mature eggs may therefore translate the same number of retrieved eggs into more embryos, which is consistent with the comparable usable embryo counts observed despite any differences in retrieval totals.

Pregnancy outcomes from the subsequent frozen embryo transfers leaned in favor of the late stimulation protocol, though not all differences were conclusive. The implantation rate, the proportion of transferred embryos that successfully implanted, was significantly higher in the late stimulation group at 68.15 percent versus 54.86 percent in the antagonist group (P equals 0.013). The clinical pregnancy rate was also numerically higher in the late stimulation group, 66.01 percent versus 55.36 percent, but this difference fell just short of statistical significance at P equals 0.051. Early miscarriage rates were comparable between the groups, at 14.85 percent and 12.9 percent respectively (P equals 0.695), providing reassurance that the simplified protocol did not compromise early pregnancy outcomes.

The biological rationale for these findings is worth unpacking. In a natural cycle, rising estradiol from the developing dominant follicle feeds back on the hypothalamus and pituitary, and the late follicular phase is characterized by a delicate interplay in which follicle-stimulating hormone is restrained while LH remains controlled until the mid-cycle surge. Starting gonadotrophins late, when a dominant follicle has already been selected, may allow the remaining cohort of smaller follicles to be recruited under conditions that more closely mimic natural physiology. The higher maturity rate of the retrieved oocytes in the late stimulation group suggests that the follicles developed in a more synchronized hormonal environment, possibly because the endogenous hormonal milieu was not flattened by antagonist administration from the earliest days of the cycle.

The authors caution that their study was a single-center trial conducted in normo-ovulatory women, a population whose regular cycles make them suitable candidates for a protocol that depends on the timing of natural follicular development. Women with irregular ovulation, such as those with polycystic ovary syndrome, may not be appropriate candidates, since the protocol relies on the body’s own selection of a dominant follicle. The investigators themselves state that larger multicenter trials are warranted to confirm the findings before the protocol can be considered for broad clinical adoption. Still, the trial, funded by the hospital, the National Natural Science Foundation of China, and the Science and Technology Commission of Shanghai Municipality, represents the first robust randomized evidence that late follicular phase stimulation can succeed without any exogenous pituitary modulator at all.

For patients, the implications are tangible. Removing the GnRH antagonist from a stimulation cycle means fewer daily injections, lower medication costs, and a simpler monitoring schedule, all without a measurable loss of usable embryos in this study population. For the freeze-all paradigm, which has grown rapidly because it avoids the ovarian hyperstimulation syndrome risk and endometrial asynchrony associated with fresh transfers, the late stimulation protocol offers a physiologically elegant complement: stimulate later, work with the cycle rather than suppressing it, freeze everything, and transfer later. As assisted reproduction continues to move toward personalized, less burdensome protocols, this Shanghai trial provides a data point suggesting that sometimes the best way to control the ovary is to trust it a little more.

Subject of Research: GnRH antagonist-free late follicular phase ovarian stimulation for freeze-all IVF/ICSI in normo-ovulatory women

Article Title: GnRH antagonist‑free late follicular phase ovarian stimulation versus an early follicular GnRH antagonist regimen in normo-ovulatory women undergoing freeze-all IVF/ICSI: a randomized controlled trial

Article References: Zhu, X., Lang, J., Zhi, Y., Wang, Q., & Fu, Y. (2026). GnRH antagonist‑free late follicular phase ovarian stimulation versus an early follicular GnRH antagonist regimen in normo-ovulatory women undergoing freeze-all IVF/ICSI: a randomized controlled trial. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02285-6

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02285-6

Keywords: IVF, ICSI, ovarian stimulation, GnRH antagonist, late follicular phase, freeze-all strategy, randomized controlled trial, fertility treatment, oocyte maturity, implantation rate, reproductive medicine, frozen embryo transfer

The study, led by Xiaoju Wan and colleagues including corresponding author Jun Tan at Jiangxi Maternal and Child Health Hospital in Nanchang, was published in the Journal of Ovarian Research. The team began with 11,524 eligible women divided into three cohorts: 2,881 with polycystic ovary syndrome, commonly abbreviated PCOS; 4,354 with diminished ovarian reserve, known as DOR; and 4,289 with tubal factor infertility, in which damaged or blocked fallopian tubes prevent natural conception. After restricting the analysis to women with complete data suitable for mediation analysis, the final sample comprised 2,507 women with PCOS, 2,425 with DOR, and 3,991 with tubal factor infertility. The outcome analyses drew on somewhat different subsets: 6,708 women for clinical pregnancy, 4,182 for pregnancy loss, and 6,523 for live birth.

The central methodological innovation of the study lies in its use of mediation analysis, a statistical framework designed to decompose an observed association into direct and indirect components. In this case, the researchers asked whether body mass index exerts part of its influence on oocyte yield, the number of eggs retrieved during an IVF cycle, through a specific intermediate variable: basal follicle-stimulating hormone, or FSH. FSH is the pituitary hormone that drives follicular growth in the ovaries, and its baseline level in the blood is a well-established marker of ovarian reserve. The logic of the mediation model is straightforward. If higher body mass index alters basal FSH levels, and if those altered FSH levels in turn change how many eggs are retrieved, then FSH functions as a mediator, carrying an indirect effect of body weight on ovarian response.

The results of this mediation analysis were nuanced. Body mass index was indeed associated with a small indirect effect on oocyte yield operating through FSH, with the proportion of the total effect mediated by FSH ranging from 5.31 to 8.21 percent across the cohorts. In other words, only a modest fraction of the relationship between body weight and egg retrieval numbers runs through the hormonal pathway the researchers measured. The direction of this indirect association was similar across all three diagnostic groups, which is precisely the kind of consistency the study was designed to detect. However, the magnitude of the effect was small and the confidence intervals were wide, particularly within the diminished ovarian reserve cohort, where fewer eggs are retrieved overall and statistical precision suffers accordingly. The authors are careful to note that the clinical relevance of this FSH-mediated pathway remains uncertain.

Where the study becomes considerably more consequential is in its findings on pregnancy loss. Obesity was significantly associated with a higher risk of miscarriage after IVF, with an odds ratio of 1.60 and a 95 percent confidence interval of 1.02 to 2.53, yielding a statistically significant result with a P value of 0.041. The researchers translated this into a clinically meaningful metric as well: a number needed to harm of 19, meaning that roughly one additional pregnancy loss could be expected for every 19 women with obesity compared with women of lower body weight. Strikingly, this elevated risk was consistent across the PCOS, diminished ovarian reserve, and tubal factor cohorts, suggesting that the miscarriage risk associated with obesity is not confined to any single infertility diagnosis but operates as a general phenomenon.

The picture for other reproductive outcomes was less definitive. Obesity showed a non-significant trend toward lower live birth rates, with an odds ratio of 0.77 and a P value of 0.078, but the authors emphasize that this analysis had only 5.3 percent statistical power, rendering it inconclusive. Power refers to a study’s ability to detect a true effect if one exists, and a power of 5.3 percent is extraordinarily low, meaning the analysis could almost certainly not have detected even a substantial difference in live birth rates. The researchers are explicit on this point: the live birth finding should be considered exploratory and hypothesis-generating, and no clinical recommendation regarding live birth can be made on the basis of this study. Meanwhile, no association was observed between obesity and clinical pregnancy, the earlier milestone at which a fetal heartbeat is typically confirmed.

These findings carry particular weight because of how they were structured. Rather than treating all IVF patients as a homogeneous group, the researchers stratified their analysis by infertility etiology, allowing them to test whether the effects of body mass index differ between women whose ovaries are polycystic, women whose ovaries are running low on eggs, and women whose reproductive tracts are mechanically obstructed. The consistency of the associations across these three biologically distinct groups is the study’s headline contribution. It suggests that whatever mechanisms link body weight to ovarian response and miscarriage, those mechanisms are not specific to the hormonal chaos of PCOS or the depleted follicular pool of DOR, but instead operate through pathways shared by all women.

Several biological explanations for such shared pathways are plausible, though the study itself was not designed to test them directly. Adipose tissue is not merely passive storage; it is an endocrine organ that secretes inflammatory cytokines, adipokines such as leptin, and enzymes that convert androgens to estrogens. Chronic low-grade inflammation associated with obesity has been implicated in impaired endometrial receptivity and compromised placental development, both of which could plausibly raise miscarriage risk independently of the cause of infertility. Similarly, the insulin resistance that frequently accompanies elevated body mass index could affect oocyte quality and early embryonic development across diagnostic categories. The modest FSH-mediated pathway identified in the study may represent one thread of this larger web, but the small proportion mediated indicates that other mechanisms, unmeasured in this analysis, likely account for most of the effect.

The study also illustrates the strengths and limits of retrospective cohort research. Because the data were collected for clinical rather than research purposes, and because the analysis was restricted to complete cases, the possibility of selection bias cannot be fully excluded; women excluded for missing data may have differed systematically from those included. The ethics committee of Jiangxi Maternal and Child Health Hospital approved the study under approval number SZYY-202604 and waived the need for informed consent given its retrospective nature, and the work was conducted in accordance with the Declaration of Helsinki. Funding came from the JXHC Key Laboratory of Fertility Preservation, and the authors declared no competing interests. As an observational study, it can establish associations but cannot prove causation, and unmeasured confounders could influence the results.

For patients and clinicians, the practical message is a measured one. Body mass index appears to matter for IVF in broadly similar ways regardless of infertility diagnosis, with the clearest and most actionable signal being the increased risk of pregnancy loss among women with obesity. The effect on egg retrieval, while real in a statistical sense, is small and partly channeled through basal FSH in a way that may not justify changes to stimulation protocols on its own. The live birth question remains open, awaiting adequately powered studies. What this research adds is a degree of generality: the conversation about weight and fertility treatment need not be segmented by diagnosis, because the evidence suggests the underlying biology is shared.

Subject of Research: The association of body mass index with IVF ovarian response and pregnancy loss across different infertility etiologies

Article Title: Consistent associations of BMI with ovarian response and pregnancy loss risk across PCOS, DOR, and tubal factor infertility: a complete-case mediation analysis of 8,923 IVF cycles

Article References: Wan, X., Yu, M., Wu, X., Huang, Z., & Tan, J. (2026). Consistent associations of BMI with ovarian response and pregnancy loss risk across PCOS, DOR, and tubal factor infertility: a complete-case mediation analysis of 8,923 IVF cycles. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02299-0

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02299-0

Keywords: body mass index, IVF, PCOS, diminished ovarian reserve, tubal factor infertility, pregnancy loss, oocyte yield, follicle-stimulating hormone, mediation analysis, obesity, reproductive medicine, miscarriage

The research team interviewed sixteen women receiving assisted reproductive treatment at two private in vitro fertilization centers in southern Türkiye. Participants were married, aged between 18 and 49, and diagnosed with female-related or unexplained infertility; women with male-factor diagnoses were excluded. Each woman took part in a face-to-face, semi-structured interview lasting 40 to 50 minutes, conducted without spouses present so that participants could speak freely. Interviews ran from February to August 2024, and recruitment stopped once data saturation was reached—the point at which successive interviews produced no new codes or themes. The researchers then applied Braun and Clarke’s six-step thematic analysis, transcribing interviews verbatim, coding them inductively, and refining themes through iterative group discussion until a coherent structure emerged.

The analysis yielded three main themes: the experience of compassion during the infertility process, the determinants of that experience, and its reflections in women’s lives. What makes the study distinctive is its grounding in Paul Gilbert’s Compassionate Mind Theory, which conceptualizes compassion as three interconnected flows—compassion directed toward oneself, compassion extended to others, and compassion received from others. Most previous research on infertile women has focused narrowly on self-compassion, typically measured with quantitative scales. By listening to women describe all three directions of compassion in their own words, the Turkish team captured a phenomenon that single-construct studies tend to miss: the way a blockage in one flow can cascade through the others.

The starkest finding concerned self-compassion, which most participants reported being unable to summon. Some women said they had never even reflected on the concept before the interview prompted them to. Others described treating themselves with a harshness they would never direct at another person, saying things to themselves they would hesitate to utter aloud for fear of causing hurt. Several reported punishing themselves through isolation, deliberately withdrawing from friends and family. One participant put it plainly: she was often harsh toward herself and criticized herself constantly, yet still tended to give compassion to others while neglecting her own boundaries. The researchers interpret this pattern through Gilbert’s model of the threat system, in which shame and self-criticism actively inhibit the capacity for self-soothing.

At the same time, the physical and psychological burden of treatment appeared to inflate the women’s need to receive compassion from others. Participants described a heightened desire to be understood, accepted without judgment, and treated with sensitivity. Spousal support emerged as the most meaningful form of compassionate behavior—partners who normalized the situation and expressed understanding helped women stop blaming themselves and become gentler with themselves. But receiving compassion proved fraught. Well-meaning remarks such as “it will happen in time” were perceived as dismissive, and several women said they could feel the difference between genuine empathy and pity. When people failed to recognize that fine line, one participant explained, their words became hurtful rather than compassionate, and she began avoiding their support altogether.

This avoidance points to one of the study’s most conceptually interesting results: fears of compassion operating across all three flows simultaneously. Some women hesitated to show themselves kindness because they believed self-compassion would fuel hope, and that hope would magnify the devastation if treatment failed. Others perceived others’ compassion as pity, insincere, or emotionally overwhelming, and responded by refusing help. Still others became reluctant to extend compassion to anyone, having felt emotionally exhausted or exploited in past relationships. In Compassionate Mind Theory terms, these are classic examples of fear of compassion—compassion experienced as a threat or vulnerability rather than a soothing resource. Crucially, the study shows these fears interacting: a woman who cannot receive kindness becomes more self-critical, and a woman who cannot be kind to herself struggles to offer kindness outward, tightening a feedback loop of withdrawal.

The determinants of these patterns were rooted in biography and culture. Participants traced their difficulties to family experiences, early criticism, and past trauma; one described how growing up with a mother’s severe depression shaped the way she now relates to herself. Others reported developing patterns of excessive compassion toward others to maintain relationships or win acceptance, often at the expense of their own emotional well-being. The sociocultural context mattered too. In Türkiye, where the study was conducted, motherhood is widely regarded as a central component of womanhood, and traditional gender norms intensify the shame and inadequacy that infertile women report. Spirituality, faith, and a sense of fate also surfaced as resources, offering comfort, meaning, and hope that helped women respond to their suffering with greater acceptance.

Perhaps the most striking reflections of compassion—or its absence—were written on the body. Women who struggled to access self-compassion described emotional eating, weight gain, excessive sleeping, and neglect of self-care, behaviors they framed as coping mechanisms rather than genuine care. Those who managed to cultivate self-compassion reported healthier lifestyle habits, improved self-care, better sleep, and greater awareness of their own needs. These accounts align with a growing quantitative literature linking self-compassion to better sleep quality, more positive body image, and fewer disordered eating behaviors. Psychologically, the contrast was equally sharp: women cut off from compassion described loneliness, hopelessness, and repetitive self-critical thoughts, while those in the flow reported self-acceptance, resilience, and a sense of being more connected to others.

Compassion also shaped whether women stayed in treatment at all. Participants described compassionate care from healthcare professionals—being listened to, having a nurse hold their hand through an egg retrieval—as fostering trust, hope, and a sense of working toward a shared goal. One woman credited a nurse who stayed beside her throughout the procedure with making a second treatment attempt possible at all. Conversely, care perceived as purely technical, indifferent to emotional needs, increased stress and anxiety about future cycles and made disengagement more likely. The authors frame this as the compassion-from-others flow generating what Gilbert calls social safeness: the emotional security that allows regulation of distress and, ultimately, self-compassion to develop.

The study’s limitations are worth noting. The sample was drawn from two private clinics in a single country and was relatively homogeneous socioeconomically; only women’s perspectives were captured, leaving partners, family members, and clinicians unheard; and a single interview offers only a snapshot of experiences that evolve across treatment stages. The researchers also acknowledge that interpreting narratives through the framework of compassion flows reflects their analytic lens rather than the participants’ own vocabulary. Even so, the implications are concrete. The authors argue that compassion-based interventions for infertility should move beyond self-compassion training to address giving and receiving compassion as well, that clinicians should avoid dismissive or pitying language in favor of validation and emotional sensitivity, and that fertility centers should watch for compassion fatigue in patients who give support while receiving little. From a policy standpoint, they call for counseling services and compassion-focused support programs within assisted reproduction centers, alongside training that equips healthcare staff to deliver care addressing emotional as well as physical needs. In a condition affecting one in six adults, the message is that kindness—in all three of its directions—is not a soft adjunct to reproductive medicine but a measurable determinant of whether women cope, stay connected, and keep going.

Subject of Research: The experience of giving, receiving, and self-directed compassion among women undergoing infertility treatment

Article Title: Flow of compassion in self, for others, and from others in the shadows of infertility: a descriptive qualitative study

Article References: Atasayar, T., Deliktaş Demirci, A., Karaçar, Y., & Kabukcuoğlu, K. (2026). Flow of compassion in self, for others, and from others in the shadows of infertility: a descriptive qualitative study. Current Psychology, 45(19), Article 1577. https://doi.org/10.1007/s12144-026-10000-3

Image Credits: AI Generated

DOI: 10.1007/s12144-026-10000-3

Keywords: infertility, compassion, self-compassion, IVF, qualitative research, Compassionate Mind Theory, compassion fatigue, mental health, reproductive medicine, women's health, empathy, psychological well-being

Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgens, and polycystic ovarian morphology. Because the hypothalamic-pituitary-ovarian axis behaves differently in these patients, with altered gonadotropin secretion patterns and often exaggerated ovarian sensitivity to hormonal cues, reproductive endocrinologists have debated for decades whether a high baseline LH level helps or harms women undergoing controlled ovarian stimulation. Some earlier hypotheses implicated elevated LH in impaired oocyte quality and reduced implantation, prompting some clinics to suppress LH before treatment. Others argued that LH plays a supportive role in theca cell androgen production, which fuels estradiol synthesis in the granulosa cells that nurture developing follicles. Until now, direct clinical evidence in PCOS patients undergoing modern IVF and intracytoplasmic sperm injection protocols has remained thin.

The research team, led by first authors Jun Liu, Xiaoyu Yu, and Fengjuan Zhang, analyzed records from 162 women with PCOS and 120 controls who all underwent IVF or ICSI followed by embryo transfer at a single reproductive medicine center. To probe whether the starting LH level mattered, the investigators stratified the PCOS patients into high-LH and low-LH groups and then systematically compared their endocrine profiles, ovarian stimulation responses, embryological parameters, endometrial characteristics, and pregnancy outcomes. The ethics committee of Sichuan Provincial Women’s and Children’s Hospital approved the protocol, and all participants provided informed consent, with the study conducted under the Declaration of Helsinki.

The baseline comparisons confirmed the expected metabolic and endocrine signature of PCOS: women with the syndrome had higher body mass index, higher testosterone, and markedly elevated anti-Müllerian hormone, the marker that reflects the enlarged pool of small antral follicles that defines the condition. Yet when it came to the mechanics of stimulation, the two PCOS subgroups diverged in an instructive way. Women in the high-LH group displayed a higher antral follicle count, needed lower total gonadotropin doses to drive multifollicular development, and reached higher estradiol concentrations on the day of the hCG trigger. Together these three signals point in one direction: a higher starting LH level was associated with enhanced ovarian responsiveness, meaning the ovaries of these women answered the stimulation drugs more vigorously and more economically.

Crucially, however, that heightened responsiveness did not translate into better reproductive outcomes. Fertilization rates were statistically indistinguishable between the high- and low-LH PCOS groups, as were embryo quality measures and the proportion of high-quality embryos produced per cycle. The stimulation duration itself was similar across groups, indicating that LH status did not accelerate or delay follicular maturation in any clinically meaningful way. When the investigators tracked the downstream pregnancy endpoints, the pattern held firm: biochemical pregnancy rates, clinical pregnancy rates, and live birth rates showed no significant differences attributable to baseline LH. The hormone that visibly reshaped the stimulation cycle left the bottom line untouched.

To place these subgroup findings in a broader context, the authors applied logistic regression modeling to identify independent predictors of clinical pregnancy across the cohort. The result was striking in what it excluded as much as in what it included. Body mass index and anti-Müllerian hormone emerged as significant independent predictors, while baseline LH failed to reach predictive significance. In practical terms, this means a clinician weighing the prognosis for a PCOS patient about to start an IVF cycle would gain more from noting her weight and her AMH level than from her pre-treatment LH value. The study also flagged a sobering signal on the other side of the pregnancy equation: miscarriage risk was elevated in PCOS patients overall compared with controls, and this risk appeared particularly concentrated in the low-LH subgroup, hinting that insufficient LH activity may be associated with a less favorable early pregnancy environment even if it does not impede conception itself.

What might explain the apparent paradox that LH shapes responsiveness without affecting outcomes? The researchers turned to an animal model for mechanistic insight, establishing a PCOS rat model and examining the ovaries for changes in the expression of the two gonadotropin receptors that orchestrate follicular development: the follicle-stimulating hormone receptor, FSHR, and the luteinizing hormone receptor, LHR. In the granulosa cells, the specialized support cells surrounding each oocyte, the PCOS rats showed a coordinated remodeling of receptor expression, with FSHR decreased and LHR increased. This local shift suggests that under PCOS conditions the ovary recalibrates its sensitivity to the two pituitary hormones, potentially compensating for systemic hormonal disturbances in ways that alter how external stimulation protocols are experienced at the cellular level.

The receptor findings carry implications beyond the laboratory. If granulosa cells in PCOS ovaries downregulate FSHR while upregulating LHR, the conventional assumption that FSH-driven stimulation proceeds through the same molecular machinery in PCOS and non-PCOS ovaries becomes questionable. Elevated local LHR expression could partly explain why high-LH PCOS patients respond so exuberantly to exogenous gonadotropins, achieving robust estradiol rises with lower drug doses. At the same time, the dysregulation of this local signaling network may contribute to the disordered folliculogenesis that characterizes the syndrome, and could interact with the elevated miscarriage risk the study documented, though the authors are careful to present the animal data as suggestive of dysregulated gonadotropin signaling rather than proof of a specific causal chain running from receptor expression to pregnancy loss.

For patients, the clinical takeaway is genuinely liberating. Women with PCOS who discover a high LH value on their pre-treatment blood panel need not fear that this number has doomed their cycle, nor should those with low LH assume their chances are compromised at the outset. The study indicates that baseline LH in PCOS is a marker of ovarian responsiveness, useful perhaps for tailoring gonadotropin starting doses and anticipating hyper-response, but not a determinant of fertilization, implantation, clinical pregnancy, or live birth. Meanwhile, the identification of BMI and AMH as independent predictors reinforces what a growing body of literature has argued: weight management and ovarian reserve assessment deserve central places in fertility counseling for PCOS patients. Elevated AMH, though it reflects the abundant follicle pool that makes PCOS ovaries so responsive, emerged alongside BMI as a predictor of clinical pregnancy, underscoring the complex double-edged role this hormone plays in the syndrome.

As with all retrospective single-center studies, the findings come with caveats that invite future work. The cohort of 282 participants is substantial but retrospective design cannot exclude residual confounding, and stimulation protocols, laboratory conditions, and transfer strategies may vary across centers and eras. Nonetheless, the study’s dual design, combining a well-stratified clinical cohort with mechanistic receptor analysis in an animal model, gives it unusual breadth for the field. By demonstrating that the luteinizing hormone value on a pre-treatment lab slip tells a story about ovarian sensitivity but not about babies, the Chengdu team has helped refocus attention on the factors that truly move the needle for women with PCOS pursuing assisted reproduction, while opening a fresh line of inquiry into how the ovary’s own receptor landscape rewires itself in one of the most common hormonal disorders of our time.

Subject of Research: The effect of basal luteinizing hormone levels on IVF/ICSI-ET outcomes in women with polycystic ovary syndrome

Article Title: Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study

Article References: Liu, J., Yu, X., Zhang, F., Liu, W., Zeng, J., & Wang, L. (2026). Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02603-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02603-5

Keywords: polycystic ovary syndrome, luteinizing hormone, IVF, ICSI, embryo transfer, anti-Müllerian hormone, ovarian stimulation, live birth rate, miscarriage risk, granulosa cells, FSHR, LHR

The study, published in Reproductive Sciences by Zhenya Yuan, Jun Shao, Ya Wen and colleagues working across reproductive medicine centers in Xuzhou, Nantong and Kunming, addresses a problem that is particularly acute in China, where PGT-A is subject to strict regulatory limitations. Without access to genetic testing, embryologists must choose which embryos to transfer based on appearance and development alone, yet visual assessment is a notoriously imperfect proxy for chromosomal health. An embryo can look flawless under the microscope and still carry an extra or missing chromosome, while a seemingly mediocre embryo may be genetically normal and fully capable of producing a live birth.

The motivation for avoiding biopsy is not merely regulatory. Although PGT-A is widely used, concerns persist that removing cells from a blastocyst, typically from the trophectoderm that later forms the placenta, could compromise the embryo’s developmental potential. The new study’s authors note that this possibility of harm, combined with the regulatory environment, made a non-invasive predictive approach a clinical necessity rather than a convenience. Their solution draws on data that fertility clinics already collect routinely, meaning the model could in principle be deployed without any change to laboratory workflow.

Technically, the researchers constructed their model using logistic regression, a statistical machine learning method that estimates the probability of a binary outcome, in this case whether a blastocyst is euploid or aneuploid. The team describes the construction as a two-step logistic regression analysis, in which predictor variables were combined to generate a risk score for each embryo. The inputs to the model fell into four categories: the results of PGT-A performed on the training embryos, which served as the ground truth labels; the dynamic development characteristics of the embryos, capturing how quickly and smoothly they progressed through early cleavage stages; the morphology of the blastocysts themselves, including the conventional features embryologists assess under the microscope; and the age of the female patient, which is one of the strongest known determinants of aneuploidy risk.

This combination of features is significant because each captures a different dimension of embryo quality. Morphokinetic data, the timing of developmental events, reflects the pace and coordination of cell divisions, and previous research has linked deviations from normal timing to chromosomal abnormalities. Blastocyst morphology, graded by systems such as the Gardner classification, summarizes the expansion of the embryo and the quality of the inner cell mass and trophectoderm. Female age contributes the statistical prior that chromosomal error rates rise steeply as oocytes age. By weaving these signals together mathematically, the model effectively formalizes what skilled embryologists do intuitively, but does so consistently and with quantified confidence.

The performance figures reported for the model are striking for a non-invasive approach. The area under the receiver operating characteristic curve, a standard measure of a classifier’s ability to distinguish between positive and negative cases across all decision thresholds, reached 0.877. When the model was applied to an independent data set, meaning embryos that played no role in training it, it achieved an accuracy rate of 77.35 percent, a precision rate of 77.49 percent, and a recall rate of 72.55 percent. The f-score, which balances precision and recall into a single number, was 74.94 percent. The model correctly identified aneuploid embryos, the true negative rate from the euploid perspective, 81.55 percent of the time, while producing a false positive rate of 18.45 percent and a false negative rate of 27.45 percent.

Perhaps the most clinically meaningful comparison in the study pits the machine learning model against the tools embryologists actually use. The model’s false positive rate in predicting euploid blastocysts was significantly lower than that of the Gardner grading system, the standard morphology-based classification, and also lower than KIDScore D5, a commercially available time-lapse algorithm that scores embryos based on their developmental dynamics. In practical terms, this means the model was less likely than conventional methods to flag an embryo as euploid when it was not, reducing the risk that patients undergo transfers destined to fail or miscarry.

The researchers went beyond retrospective prediction and examined what happened when the model was used to make real selection decisions. When blastocysts for frozen embryo transfer were chosen using the model’s predictions, the transfer outcomes improved significantly compared with cycles in which embryos were selected by Gardner grade alone. This is a crucial distinction, because a model can score well on statistical metrics yet fail to change clinical results. Here, the improvement in frozen embryo transfer outcomes suggests that the model’s predictions translate into genuinely better choices about which embryos to place into patients.

The study builds on a growing body of work applying artificial intelligence to embryo assessment. Earlier efforts by some of the same authors developed an artificial intelligence model for predicting blastocyst euploidy specifically within PGT-A treatment cycles, where genetic results are available to train and validate algorithms. Other groups have compared deep learning-based embryo selection against manual morphology assessment in randomized trials, and meta-analyses of thousands of embryos have examined how morphological and morphokinetic features correlate with aneuploidy. Time-lapse imaging studies have identified specific dynamic events, such as blastocyst contractions, that associate with chromosomal abnormality and reduced implantation potential. The new work extends this lineage into territory where genetic ground truth is unavailable at the point of care, which is precisely where the clinical need is greatest.

The implications reach well beyond China’s regulatory landscape. Even in countries where PGT-A is freely available, the procedure adds cost, requires embryo biopsy, and remains debated, with large randomized trials yielding mixed conclusions about whether it improves live birth rates per transfer cycle started. A validated non-invasive predictor could serve as a triage tool everywhere, helping clinics prioritize embryos for transfer or for biopsy, sparing patients unnecessary procedures, and potentially reducing the number of embryos subjected to manipulation. Because the model relies on development dynamics, morphology and maternal age, data captured in virtually every modern IVF laboratory, adoption barriers would be low compared with approaches requiring new imaging hardware or genetic assays.

Caution is still warranted. A model with 77 percent accuracy and a 27 percent false negative rate is a powerful aid to decision-making, not a replacement for genetic diagnosis when a definitive answer is required, and the authors themselves frame the tool as a way to select euploid embryos as far as possible rather than with certainty. External validation across diverse patient populations, laboratory protocols and imaging systems will be essential before widespread deployment, and the field has seen predictive models falter when moved between centers. Nevertheless, the study represents a concrete step toward a long-sought goal: choosing the best embryo for transfer using only what the embryo reveals about itself, non-invasively, as it grows. For the millions of couples undergoing IVF worldwide, an algorithm that quietly reads the developmental story of each blastocyst and tips the odds toward a healthy pregnancy is a development worth watching closely.

Subject of Research: Machine learning prediction of euploid blastocysts in IVF without preimplantation genetic testing for aneuploidy

Article Title: The Building and Application of a Machine Learning Model on Predicting Euploid Blastocysts in IVF Treatments Without PGT-A

Article References: Yuan, Z., Shao, J., Wen, Y., Yuan, M., Bai, M., Song, X., & Huang, X. (2026). The Building and Application of a Machine Learning Model on Predicting Euploid Blastocysts in IVF Treatments Without PGT-A. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02230-4

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02230-4

Keywords: IVF, machine learning, euploid blastocyst, PGT-A, aneuploidy, embryo selection, logistic regression, morphokinetics, blastocyst morphology, frozen embryo transfer, reproductive medicine, non-invasive prediction